HR 1672 · in committee · significant
Maintaining Investments in New Innovation Act
- healthcare
What this bill does
- This bill extends the Medicare drug price negotiation program's approval timeline for genetically targeted drugs to 11 years instead of 7.
- It affects patients, Medicare, drug manufacturers developing genetic therapies, and CMS negotiators.
- The change takes effect when the Medicare Drug Price Negotiation Program begins in 2026.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might extending the negotiation timeline from 7 to 11 years affect drug manufacturers' willingness to develop new genetic therapies versus other treatments?
- 02
What trade-offs exist between giving manufacturers more time to recoup development costs and ensuring Medicare patients access to genetic drugs at lower prices?
- 03
How would this extended timeline impact patients currently waiting for genetic therapies that might be delayed or priced higher during the additional protection period?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-NC-1
Donald G. Davis
Citizen cosponsors
0
In Congress
42/ 435
House Reps cosponsoring
Introduced 2025-02-27
Joining the bill
Claudia Tenney
R-NY-24 · original
John Joyce
R-PA-13 · original
Scott H. Peters
D-CA-50 · original
Mariannette Miller-Meeks
R-IA-1 · original
Richard Hudson
R-NC-9 · original
Dan Crenshaw
R-TX-2 · original
Rick W. Allen
R-GA-12 · original
Blake D. Moore
R-UT-1 · original
Aaron Bean
R-FL-4 · original
Joseph D. Morelle
D-NY-25 · original
Josh Gottheimer
D-NJ-5 · original
Beth Van Duyne
R-TX-24 · original
+ 30 more
Legislative timeline
2025-02-27 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-27 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-27 · IntroReferral
Introduced in House
2025-02-27 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.